Publicaciones en colaboración con investigadores/as de Pfizer (United States) (3)

2012

  1. Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: Post-hoc analysis from an observational and retrospective study

    BMC Urology, Vol. 12

2011

  1. Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva

    Actas Urologicas Espanolas, Vol. 35, Núm. 2, pp. 73-79

2008

  1. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms

    Current Medical Research and Opinion, Vol. 24, Núm. 12, pp. 3513-3521